N@N

CHU, GERN, EK, DDSS, IPG, STSI. Top Gainers With Lowest Price Friction In Morning Trade Today

^{Published on 2009-07-06 08:11:39, Last Modified on 2010-12-22 14:25:46 - WOPRAI}
 

July 6, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for July 6, 2009. Since late October market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This afair market makinga requirement is designed to prevent market makers from manipulating stock prices. Here is a list of the top companies with the largest gains this morning and lowest price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. China Unicom Hong Kong (NYSE: CHU), Geron (NASDAQ: GERN), Eastman Kodak (NYSE: EK), Labopharm (NASDAQ: DDSS), Interpublic Group of Companies (NYSE: IPG) and Star Scientific (NASDAQ: STSI). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

Symbol Change % BuyVol Buy% SellVol Sell% NetVol Friction

CHU $0.35 2.78% 206,180 47.82% 171,838 39.85% 34,342 981

GERN $0.25 3.27% 1,240,026 52.77% 1,109,024 47.20% 131,002 5,240

EK $0.21 7.78% 547,885 58.66% 304,170 32.57% 243,715 11,605

DDSS $0.19 7.72% 907,537 52.20% 830,781 47.79% 76,756 4,040

IPG $0.14 2.88% 610,407 47.58% 532,556 41.51% 77,851 5,561

STSI $0.13 15.06% 1,938,123 62.80% 1,143,841 37.07% 794,282 61,099

Click here to view chart:

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar gains (Change) and very low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows CHU with a dollar gain this morning of +$0.35 and a Friction Factor of 981 shares. That means that it only takes 981 more shares of buying than selling to move CHU higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

China Unicom (Hong Kong) Limited (NYSE: CHU) provides telecommunications services in the People's Republic of China. The company offers GSM telephone and related services, fixed-line voice and value-added services, broadband and other Internet-related services, information communications technology services, business and data communications services, and advertising and media services, as well as long distance services. As of December 31, 2008, it served approximately 133.365 million GSM subscribers in 31 provinces, municipalities, and autonomous regions in the Mainland China. China Unicom (Hong Kong) Limited has a strategic cooperation agreement with Baidu Inc. to jointly develop wireless search services. The company was formerly known as China Unicom Limited and changed its name to China Unicom (Hong Kong) Limited in October 2008. China Unicom (Hong Kong) Limited was founded in 2000 and is based in Central, Hong Kong. China Unicom (Hong Kong) Limited operates as a subsidiary of China Unicom (BVI) Limited.

Geron Corporation (NASDAQ: GERN), a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. The company develops a range of anti-cancer therapies, including anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines, as well as focuses on the development of products using telomerase as a marker for cancer diagnosis, prognosis, patient monitoring, and screening. Its products include GRN163 and GRN163L, which are telomerase inhibitors for the treatment of chronic lymphoproliferative diseases, solid tumors, non-small cell-lung cancer, breast cancer, and multiple myeloma, which are in Phase I trials; and GRNVAC1, a telomerase cancer vaccine that is in Phase II clinical trial for the treatment of acute myelogenous leukemia. Geron Corporation also develops human embryonic stem cell-based therapeutics, with its spinal cord injury treatment. The company has research, development, and commercialization license agreement with Merck & Co., Inc. to use telomerase in non-dendritic cell cancer vaccines; and a license agreement with Sienna Cancer Diagnostics to detect telomerase for in vitro cancer diagnosis. Geron Corporation was founded in 1990 and is based in Menlo Park, California.

Eastman Kodak Company (NYSE: EK) provides imaging technology products and services to the photographic and graphic communications markets worldwide. It operates in three business segments: Consumer Digital Imaging Group (CDG); Film, Photofinishing, and Entertainment Group (FPEG); and Graphic Communications Group (GCG). The CDG segment offers consumer digital products that include digital still and video cameras, digital picture frames, imaging accessory products, and snapshot printers and printer media; retail kiosks and consumables, consumer and retailer software workflows, remote business monitoring, retail store merchandising and identity programs, and after sale service and support; imaging sensors; and all-in-one inkjet printers. This segment also provides online merchandise and sharing services. The FPEG segment comprises traditional photographic products and services used for consumer, professional, and industrial imaging applications, as well as those products and services used in the creation of motion pictures. It manufactures and markets films (motion picture, consumer, professional, industrial, and aerial), and one-time-use cameras. The GCG segment digital and traditional prepress equipment and consumables, including plates, chemistry, and media; workflow software and digital controller development; color, and black and white electrophotographic equipment and consumables; commercial inkjet printing systems; wide-format inkjet inks and media; production and workgroup document scanners; and micrographic peripherals and media. It also provides imaging services; and maintenance and professional services for other manufacturers' products. This segment serves various customers in the creative, in-plant, data center, commercial printing, packaging, newspaper, and digital service bureau market segments. Eastman Kodak Company has collaboration with Pitney Bowes for imaging and workflow solutions. The company was founded in 1880 and is headquartered in Rochester, New York.

Labopharm Inc. (NASDAQ: DDSS), a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies. It offers once-daily formulation of the analgesic tramadol under the RYZOLT brand name for the treatment of severe chronic pain in adults. The company sells RYZOLT primarily in the United States, Europe, Canada, South Korea, and Australia. Labopharma�s products in pipeline include once-daily formulation of trazodone, a serotonin antagonist reuptake inhibitor for the treatment of depressive disorder. Its product candidates in clinical development based on Contramid platform comprise twice-daily formulation of tramadol plus acetaminophen to address acute pain; and Abuse Deterrent Platform to provide safer medications through resistance to the uncontrolled release of the active ingredient after actions, such as breaking, chewing, crushing and heating, or consumption with alcohol. Its product candidates in clinical development based on the Polymeric Nano-Delivery System platform comprise lipid-and preservative-free formulation of the intravenous anaesthetic agent propofol; and SN-38, which is the active metabolite in the prescribed intravenous colon cancer drug irinotecan. Labopharm was formerly known as Centre de recherche appliquee pharmaceutique CRAP inc. and changed its name to Labopharm Inc. in September 1994. The company was founded in 1990 and is headquartered in Laval, Canada.

The Interpublic Group of Companies, Inc. (NYSE: IPG), together with its subsidiaries, provides advertising and marketing services worldwide. The company offers consumer advertising, as well as mobile and search engine marketing. It operates through two segments, Integrated Agency Network (IAN) and Constituency Management Group (CMG). The IAN segment provides a range of advertising and marketing communications services, as well as marketing services. The CMG segment provides services, including public relations, meeting and event production, sports and entertainment marketing, corporate and brand identity, and strategic marketing consulting. The company was formerly known as McCann-Erickson Incorporated and changed its name to The Interpublic Group of Companies, Inc. in January 1961. The Interpublic Group of Companies was founded in 1902 and is based in New York, New York.

Star Scientific, Inc. (NASDAQ: STSI), together with its subsidiaries, engages in the development, implementation, and licensing of tobacco curing technology that prevent the formation of carcinogenic toxins present in tobacco and tobacco smoke, primarily the tobacco-specific nitrosamines (TSNAs). It also manufactures, sells, markets, and develops low-TSNA dissolvable smokeless tobacco products, such as ARIVA, a compressed powdered tobacco cigalett pieces; and STONEWALL Hard Snuff, a non-fermented spit-free hard tobacco product for moist snuff users designed to provide adult tobacco users with an alternative to cigarettes. In addition, the company develops pharmaceutical products that have a botanical tobacco-based component designed to treat tobacco dependence; and neurological conditions, including Alzheimera�s disease, Parkinsona�s disease, schizophrenia, and depression. It sells its smokeless tobacco products through tobacco distributors in the United States. Star Scientific, Inc. was founded in 2000 and is based in Petersburg, Virginia.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,550,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. None of the companies in this report have paid to be included in this report. From time to time we will mention a company that may have previously paid $995 per month for market data purchased from BUYINS.NET. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET, FRICTION FACTOR and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net